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ABSTRACT
Objective:We have evaluated the sensitivity and specificity of a new synthetic peptide-based species-
specific enzyme immunoassay (EIA) for detection of Chlamydia trachomatis IgG and IgA antibod-
ies.
Methods: Synthetic peptides derived from variable domain IV of major outer membrane protein
(MOMP) were used as antigen in indirect EIA. IgG and IgA antibodies were measured in parallel
with serum samples from C. trachomatis culture positive, culture negative, and antigen positive
patients, and women with suspected C. trachomatis infection and blood donors. Sera from children
under 15 years of age were used as controls.
Results: Culture positive women, culture positive men, and antigen positive women had positive
peptide serology in 84.2%, 61.3%, and 93.1% of the cases, respectively. Among C. trachomatis
suspected women, the antibody prevalence was 63.6%. Randomly collected blood donors showed a
prevalence of 21.5%. Children with C. pneumoniae antibodies determined with the microimmuno-
fluorescence (MIF) method did not show any reactivity in the C. trachomatis peptide EIA.
Conclusions: The results suggest that the new EIA test is highly specific for C. trachomatis, and
C. pneumoniae antibodies do not interfere. Both IgG and IgA antibodies appear within at least 2
weeks in acute phase of infection among both culture positive and culture negative patients. Infect.
Dis. Obstet. Gynecol. 5:349-354, 1997. (C) 1998 Wiley-Liss, Inc.
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halamydia
trachomatis is a leading cause of sexu-
lly transmitted disease, frequently occurring
worldwide. It has been estimated that 25% of
infected men and 50-80% of women may be
asymptomatic,e-4 These individuals have a risk
to further transmit the infection without any
knowledge of the disease. In addition, the asymp-
tomatic infection may lead to severe complica-
tions including infertility due to tubal damage,
chronic abdominal pain, or chronic arthritis. Test-
ing first void urine, made possible by the sensitive
assays relying on the amplification of chlamy-
dial DNA,s,6 complements the earlier established
methods, e.g., isolation in cell culture and detec-
tion of chlamydial antigen. 7,s The diagnosis of past
or complicated infections is not usually possible
by using these methods as swabbing the infected
site is not possible without invasive procedures or
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chlamydial particles may not be present at the
site.
Another method to diagnose complicated chla-
mydial infections is to measure antibodies against
C. trachomatis in serum or secretions.9 The "gold
standard" of chlamydia serology is the microimmu-
nofluorescenc (MIF) test.1 Several enzyme irn-
munoassay (EIA)-based tests have been developed
for the detection of C. trachomatis antibodies. 11,1z
However, during chlamydial infection, antibodies
are also formed against the common antigenic epi-
topes present in all members of the genus Chlamyd-
ia. When whole bacteria are used as antigen in
EIAs, the detection of these cross-reacting antibod-
ies makes species-specific diagnosis difficult.
We have developed a synthetic peptide-based
C. trachomatis species-specific EIA test to detect
IgG and IgA antibody responses in humans. The
peptides used are derived from the variable domain
IV (VD IV) region of the major outer membrane
protein (MOMP) of C. trachomatis. The synthesized
peptides do not share any sequence homology with
C. pneumoniae MOMP.
SUBJECTS AND METHODS
Peptide-Based EIAs
Species-specific C. trachomatis IgG and IgA EIAs
are based on synthetic peptides derived from VD
IV. Peptides were used as antigen in solid phase in
conventional indirect EIA (Labsystems, Helsinki,
Finland). Bound antibodies were detected either
with anti-human-IgG-horseradish peroxidase
(HRP) or with anti-human-IgA-HRP conjugates.
Binding was visualized with tertramethyl benzi-
dine (TMB) as a chromogen. Samples were diluted
10-fold (20 + 180 pl) in the sample diluent in both
tests. The tests were run according to the manu-
facturer’s instructions. The result was interpreted
to be positive if the signal/cutoff value (S/C) was
> or negative if S/C was <1. C. trachomatis IgG or
IgA positive human serum verified by MIF was
used as the positive control in every run. Cutoff
was defined 0.3 x absorbance value of the positive
control.
Patient Groups
Sera from patients visiting the Helsinki City Out-
patient Clinic for Venereal Diseases with sus-
pected C. trachomatis infection were studied. C. tra-
chomatis culture results were available from these
patients. Also paired sera collected at 2 week in-
tervals were available from women and men with
initially positive and negative C. trachomatis culture
results. The first blood specimen was drawn at the
same visit when the sample for C. trachomatis cul-
ture was taken. All cases were suspected to have an
acute C. trachomatis infection. Sera from patients
with positive chlamydial antigen detection test
(Chugai/Gen-Probe, Tokyo, Japan) were from Mo-
tomura Obstetrics and Gynecology Clinic (Na-
gasaki, Japan), and samples from C. trachomatis sus-
pected but not confirmed female age unknown
were from Falco Commercial Laboratory (Kyoto,
Japan).
As controls, sera from randomly collected (sex
and age range unknown) blood donors from the
Finnish Red Cross Blood Transfusion Center, chil-
dren aged 1-7 years, collected during a hepatitis A
virus (HAV) epidemic during autumn 1994 (chil-
dren 1) from the Department of Virology, Aurora
Hospital, and children aged 1-15 years with sus-
pected viral and/or chlamydial illnesses (children 2)
from the Department of Virology, University of
Helsinki, were tested. Sera from the children 2
group were tested for the presence of C. pneumoniae
antibodies by the MIF method developed at the
Department of Virology, University of Helsinki.
Antibodies of IgG and IgM classes to C. pneumoniae
were detected in 46% and 14% of the cases, respec-
tively.
RESULTS
The C. trachomatis IgG and IgA antibody preva-
lence by the peptide-based EIA in different pa-
tient and control groups is presented in Table 1.
84.2% of C. trachomatis culture positive women,
61.3% of culture positive men, and 93.1% of Chla-
mydia antigen positive women were EIA positive.
In the culture negative group, 45.3% ofwomen and
38.3% of men were seropositive. A serostatus with
an IgA antibody response but no IgG antibodies
was more frequently seen in males than in females.
Of culture negative men, 10.8% had detectable IgA
antibodies without IgG response.
Randomly collected blood donors showed an an-
tibody prevalence of 21.5%. Only two children had
C. trachomatis antibodies detectable by the EIA.
One was an IgG positive 6-month-old baby (chil-
dren group) with probable maternal antibodies to
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TABLE I. Prevalence of C. trachomatis antibodies in different patient and control groups
Only IgG Only IgA lgG + IgA Total
Group N response (%) response (%) response (%) response (%)
Women
Culture positive 82 13.4 2.4 68.3 84.2
Antigen positive 44 15.9 0.0 77.3 93.
Suspected only 44 29.6 4.6 29.6 63.6
Culture negative 148 15.6 0.7 29.0 45.3
Men
Culture positive 80 10.0 5.0 46.3 61.3
Culture negative 120 15.8 10.8 1.7 38.3
Controls
Blood donors 247 1.3 5.3 4.7 21.5
Children 67 1.5 0.0 0.0 1.5
Children 2 85 0.0 1.2 0.0 i.2
aThe total response is a sum of only IgG, only lgA, and simultaneous IgG and IgA (IgG + IgA) responses. Children children aged below 7 years,
children 2 children aged below 15 years, sera tested with C. pneumoniae MIF.
C. trachomatis and the other was an IgA antibody
positive 15-year-old male (children 2 group) with a
clinical diagnosis of reactive arthritis in the knee.
This patient did not have C. pneumoniae IgG and
IgM antibodies determined by MIF.
C. trachomatis antibody responses seen in paired
sera from culture positive and culture negative pa-
tients of the sexually transmitted disease (STD)
clinic are presented in Table 2. Patients were clas-
sified as follows: 1) stable IgG and IgA antibody
titers (the change of S/C value was less than 2); 2)
IgG and IgA antibody titer rises (the change of S/C
value was more than 2); 3) seroconversions (the
first sample was negative and second was positive);
4) negative (both samples were negative). All IgG
titer rises were detected in the group of culture
positive men. Seroconversion in IgG antibodies
was found among culture positive patients; only
one case was a women. Seroconversion in IgA an-
tibodies was seen in three culture positive men and
three culture negative women.
In the acute phase infection, IgG and IgA sero-
conversions or titer rises in the same patient were
compared in Table 3. Two culture negative women
with IgA seroconversion had already high IgG an-
tibody levels in the first serum (F1 and F2). One
culture negative women had an IgA seroconversion
but remained IgG negative (F3). One culture posi-
tive women with IgG seroconversion was IgA nega-
tive (F4). All men with seroconversion were culture
positive. Among the males with IgA seroconver-
sion, two showed IgG titer rises (M1 and M2) and
one IgG seroconversion (M3). The other male with
IgG seroconversion had already stable IgA levels
(M4). The two other IgG titer rises among the cul-
ture positive men showed either a decreasing (MS)
or stable (M6) IgA level.
DISCUSSION
Synthetic peptides offer an alternative method to
create highly specific and sensitive serological tests
for diagnosis of microbial infections. 13 They pro-
vide a possibility to design site-specific antigenic
determinants for distinction between type-specific
antibodies. 14 Since the MOMP of C. trachomatis is
an antigenically complex protein having cross-
reactive and species-specific epitopes,
is the speci-
ficity can be achieved only by using synthetic pep-
tide as an antigen.
16 For a more accurate determi-
nation of species-specific epitopes with the highest
sensitivity, the continuous antigenic epitopes of C.
trachomatis MOMP polypeptide were studied by
using the epitope scanning method. Systematic
scanning with overlapping peptides derived from
the MOMP polypeptide showed species-specific
antigenic determinants, which reacted with C. tra-
chomatis antibody positive human sera. 17
The difficulty in the serology of chlamydial in-
fections is the close relationship of C. trachomatis
and C. pneurnoniae.
8 Common antigenic structures
also in major polypeptides such as MOMP and
kd60 may lead to the cross-reactions interfering
with the diagnosis of C. trachomatis seroreactivity.
Specificity of the assay is a question of importance
in chlamydial serology since the epidemiology and
transmission routes of C. trachomatis and C. pneu-
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 351CHLAMYDIA TRACHOMATIS EIA NJt’RVJI’NENET AL.
TABLE 2. Frequency of C. trachomatis antibody responses in paired sera from culture positive and culture
negative STD patients in different phases
Culture positive Culture negative
Female Male Female Male
Phase IgG IgA IgG IgA IgG IgA IgG IgA
Stable 10 6 7 10 29 19 15 14
2 x titer rise 0 0 4 0 0 0 0 0
Seroconversion 0 2 3 0 3 0 0
Negative 5 2 2 30 36 18 19
Total 12 15 15 59 58 33 33
aThe first sample is negative and the second sample is positive.
TABLE 3. Comparison of C. trachomatis IgG and IgA seroconversions or titer rise and culture result
SIC IgG SIC IgA
Culture Sex st sample 2nd sample st sample 2nd sample
Negative
Positive
FI 9.25 8.43 0.42 4.73
F2 7.06 6.73 0.31 1.90
F3 0.93 0.86 0.52 1.52
F4 0.41 I. 14 0.48 0.58
M 1.36 3. 0.66 I. 12
M2 1.96 4.68 0.48 1.60
M3 0.76 8.97 0.27 1.54
M4 0.47 1.31 1.96 2.02
M5 1.27 2.89 4.19 2.03
M6 1.49 7.30 2.09 2.18
aF female; M male.
moniae infections are very different. The immuno-
dominant epitopes derived from the VD IV region
of C. trachomatis MOMP do not show any sequence
homology with corresponding polypeptide of C.
pneumoniae. The specificity of our assay was tested
using serum samples from children aged 1-15
years. We selected these sera since most of the C.
trachomatis infections are sexually acquired and are
considered to be rare in this age group in Finland.
The prevalence of C. trachomatis-specific antibod-
ies among children was very low as expected: 2 of
152 children were seropositive. A 6-month-old
baby had IgG antibodies, probably of maternal ori-
gin, and a 15-year-old male with reactive arthritis
had IgA antibodies but not IgG antibodies. We
could not ascertain whether this was a case of re-
active arthritis following a genital infection. Al-
though almost half of the children in group 2 had
antibodies to C. pneumoniae by MIF, none of them
had positive reaction in peptide EIA. This suggests
that antibodies to C. pneumoniae do not interfere
with C. trachomatis EIA.
To evaluate the specificity of the new assay, sera
from unselected blood donors were tested by pep-
tide EIA. The average age of Finnish blood donors
is 40.3 years, with the frequency of men and
women being 55% and 45%, respectively (Vihi-
s6yrinki, personal communication). The observed
prevalence of C. trachomatis antibodies (IgG, IgA,
or both) was 21.5% (Table 1). This is in agreement
with an earlier study done in Finland: Saikku 19 has
shown by using MIF that in patients with infection
suspected to be of chlamydial origin the prevalence
of both C. trachomatis and C. pneumoniae infections
increases with the age. From age 30 years in both
sexes the prevalence of C. trachomatis antibody is
over 10%, reaching the maximum of almost 20% in
women aged 31-40 years. Although men have more
C. pneumoniae antibodies in all age groups, women
have more C. trachomatis cases. 19
The sensitivity of the peptide-based C. tracho-
matis EIA was tested with sera from Finnish female
and male and Japanese female patients with an
acute C trachomatis genital infection. Among cul-
ture positive patients, the antibody prevalence was
84.2% in women and 61.3% in men. Of the 44
Japanese women with a positive cervical chlamyd-
ial antigen detection test, 93.2% had antibodies de-
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tectable by the peptide EIA. Patients with clini-
cally suspected C. trachomatis infection that could
not be confirmed by culture frequently had anti-
body response detectable by the EIA: 45.3% of the
Finnish women, 63.6% of the Japanese women,
and 38.3% of the Finnish men had C. trachomatis
antibodies. This may reflect that while these pa-
tients did not have a confirmed infection during
that visit, some of them might have had an infec-
tion earlier or they had had an acute infection that
could not be detected due to insensitivity of the
culture or the antigen detection tests.
There were several differences in the C. tracho-
marls antibody status between men and women.
The seropositivity among the women with or with-
out the culture confirmation was higher than that
among men. This is in accordance with earlier re-
ports on the antibody prevalence tested by MIF1
suggesting that the antibodies are formed more of-
ten in women, perhaps due to the larger anatomical
area affected. The difference also could be seen
when testing paired sera. Most of the seroconver-
sions and all of the titer rises occurred among cul-
ture positive men. All but one of the culture and
antibody positive women had already developed
IgG/IgA antibodies in the stable phase. This might
suggest that either women on average are serocon-
verted earlier and faster or they become symptom-
atic later. Among culture negative patients there
were three IgA seroconversions: two women had
already stable IgG levels suggesting a reinfection
and one was IgG negative, perhaps primary early
stage infection.
Both culture positive and culture negative men
more frequently showed a serostatus with IgA re-
sponse without IgG antibodies than corresponding
women (5.0% vs. 2.4% and 10.8% vs. 0.7%, Table
1). Among Japanese antigen positive women, no
pure IgA response was found. In addition, three
IgG seroconverted culture positive men had al-
ready stable or decreasing IgA levels.
There is evidence that serum IgA antibodies
may be indicative of an active inflammatory pro-
cess. IgA positivity has been associated with trans-
ference of the organism between partners as well as
indirectly with women with evidence of tubal pa-
thology,z-z4 Up to 80% of females with C. tracho-
matis infection have been reported to be asymp-
tomatic,e-4 This is supported by the finding that
10% of the blood donors in this study had IgA
antibodies. This may indicate that the rate of
chronic but asymptomatic infections is remarkable
among the normal population. Since the conse-
quences of chronic infection especially among
women are severe, i.e., may lead to infertility, the
screening of antibodies to C. trachomatis among the
sexually active population is important.
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